No Data
No Data
China Meheco Group Co., Ltd.'s (SHSE:600056) Business Is Yet to Catch Up With Its Share Price
With a median price-to-earnings (or "P/E") ratio of close to 29x in China, you could be forgiven for feeling indifferent about China Meheco Group Co., Ltd.'s (SHSE:600056) P/E ratio of 29x. However,
[Broker Focus] CMB International expects China's pharmaceutical industry to return to healthy growth this year
Jinwu Financial News | CMB International said that since the beginning of the year, the MSCI China Healthcare Index has fallen 22.7%, outperforming the MSCI China Index by 23.3%. Looking ahead to 2024, China's pharmaceutical industry is expected to return to healthy growth as industry regulation is normalized and the impact of the COVID-19 base gradually subsides. The bank continues to be optimistic about BeiGene (06160), Cinda Biotech (01801), Columbotai (06990), Giant Biotech (02367), Gushengtang (02273), and Mindray Healthcare (300760). Additionally, it is recommended to focus on high-dividend stocks with steady performance, such as Regal Healthcare
Yamato: First Sinopharm Holdings “Buy” Rating Target Price HK$25
Daiwa released a research report stating that Sinopharm Holdings (01099) has a “buy” rating for the first time, with a target price of HK$25. According to the report, Sinopharm has an unquestionable leading position in China's pharmaceutical distribution industry, with a market share of 25%. Based on a favorable policy environment and competitive pattern, it is expected that the time is ripe for further integration of the industry. It is believed that investing in Sinopharm is a long-term investment option. It is expected that its supply chain service capabilities will have a synergy effect with its traditional distribution business and bring room for improvement in profit margins. The bank predicts that under the influence of anti-corruption in the industry last year, Sinopharm's profit for the full year of last year will fall 3% year on year, but regulatory factors believe
Guojin Securities: Innovative drugs are an important field for the implementation of scientific and technological progress. Overall, performance will rise simultaneously with market performance
Guojin Securities released a research report saying that global innovative drugs are an important field for realizing scientific and technological progress, and China's innovative drug industry chain is on the rise. With the full restoration of in-hospital diagnosis and treatment, the introduction of national incentives and support policies for innovative drugs one after another, and the pace of internationalization of Chinese pharmaceutical companies, the industry as a whole will usher in simultaneous improvements in performance and market performance. It is recommended to invest in two types of targets: 1) choose a racetrack, preferring domestic targets mapped by metabolic, neurological, and self-immune indications and cutting-edge innovators in overseas breakthroughs; 2) select leaders, which are optimistic about bottom-up and internationalization breakthroughs. Recommended attention: Cinda Biotech (01801), Kangfang Biology
Is The Market Rewarding China Meheco Group Co., Ltd. (SHSE:600056) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?
It is hard to get excited after looking at China Meheco Group's (SHSE:600056) recent performance, when its stock has declined 4.3% over the past three months. It is possible that the markets have ig
Meheco's Unit Gets Nod to Raise Specifications for Piperacillin Sodium for Injection
China's National Medical Products Administration approved the application of China Meheco Group's (SHA:600056) unit to increase specifications for piperacillin sodium for injection after the drug pass
No Data